Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

500 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study.
Garcia-Carbonero R, Supko JG, Maki RG, Manola J, Ryan DP, Harmon D, Puchalski TA, Goss G, Seiden MV, Waxman A, Quigley MT, Lopez T, Sancho MA, Jimeno J, Guzman C, Demetri GD. Garcia-Carbonero R, et al. Among authors: harmon d. J Clin Oncol. 2005 Aug 20;23(24):5484-92. doi: 10.1200/JCO.2005.05.028. J Clin Oncol. 2005. PMID: 16110008 Clinical Trial.
Treatment of the patient with stage M0 soft tissue sarcoma.
Suit HD, Mankin HJ, Wood WC, Gebhardt MC, Harmon DC, Rosenberg A, Tepper JE, Rosenthal D. Suit HD, et al. Among authors: harmon dc. J Clin Oncol. 1988 May;6(5):854-62. doi: 10.1200/JCO.1988.6.5.854. J Clin Oncol. 1988. PMID: 3367188
Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity.
Puchalski TA, Ryan DP, Garcia-Carbonero R, Demetri GD, Butkiewicz L, Harmon D, Seiden MV, Maki RG, Lopez-Lazaro L, Jimeno J, Guzman C, Supko JG. Puchalski TA, et al. Among authors: harmon d. Cancer Chemother Pharmacol. 2002 Oct;50(4):309-19. doi: 10.1007/s00280-002-0498-3. Epub 2002 Jul 31. Cancer Chemother Pharmacol. 2002. PMID: 12357306 Clinical Trial.
Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas.
DeLaney TF, Spiro IJ, Suit HD, Gebhardt MC, Hornicek FJ, Mankin HJ, Rosenberg AL, Rosenthal DI, Miryousefi F, Ancukiewicz M, Harmon DC. DeLaney TF, et al. Among authors: harmon dc. Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):1117-27. doi: 10.1016/s0360-3016(03)00186-x. Int J Radiat Oncol Biol Phys. 2003. PMID: 12829150 Clinical Trial.
Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.
Garcia-Carbonero R, Supko JG, Manola J, Seiden MV, Harmon D, Ryan DP, Quigley MT, Merriam P, Canniff J, Goss G, Matulonis U, Maki RG, Lopez T, Puchalski TA, Sancho MA, Gomez J, Guzman C, Jimeno J, Demetri GD. Garcia-Carbonero R, et al. Among authors: harmon d. J Clin Oncol. 2004 Apr 15;22(8):1480-90. doi: 10.1200/JCO.2004.02.098. J Clin Oncol. 2004. PMID: 15084621 Clinical Trial.
Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514.
Kraybill WG, Harris J, Spiro IJ, Ettinger DS, DeLaney TF, Blum RH, Lucas DR, Harmon DC, Letson GD, Eisenberg B; Radiation Therapy Oncology Group Trial 9514. Kraybill WG, et al. J Clin Oncol. 2006 Feb 1;24(4):619-25. doi: 10.1200/JCO.2005.02.5577. J Clin Oncol. 2006. PMID: 16446334 Clinical Trial.
500 results